Skip to main content

14 Result(s)

within P. Biron Remove this filter Medicine & Public Health Remove this filter

and

  1. No Access

    Article

    Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)

    This report retrospectively analyzed the outcome of 91 patients aged 60 years or older with refractory/relapsed (R/R) classical Hodgkin's lymphoma (cHL) who underwent autologous stem cell transplantation (ASCT...

    A Stamatoullas, P Brice, M S Gueye, S Mareschal… in Bone Marrow Transplantation (2016)

  2. No Access

    Article

    The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT

    Both auto-SCT and reduced intensity allo-SCT (RIST) are employed in the treatment of relapsed follicular lymphoma (FL). We have analysed the outcome of these two transplant procedures when used as a first tran...

    S P Robinson, C Canals, J J Luang, H Tilly, C Crawley… in Bone Marrow Transplantation (2013)

  3. No Access

    Article

    Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer

    Pegase 03 is a multicenter prospective randomized phase III trial evaluating the impact of first-line high-dose chemotherapy (HDC) with stem cell support on overall survival (OS), disease-free survival (DFS) a...

    P Biron, M Durand, H Roché, T Delozier, C Battista… in Bone Marrow Transplantation (2008)

  4. No Access

    Article

    Anticorps anti-VEGF: un emploi universel?

    Il y a 25 ans, la convergence de plusieurs stratégies de recherches indépendantes vers un petit nombre de gènes a permis de fonder le paradigme des oncogènes, les «gènes de cancer» dont les dé règlements pertu...

    I. Ray-Coquard, T. Bachelot, C. Saba, C. Confavreux, J.-F. Brantus, F. Rustam… in Oncologie (2006)

  5. No Access

    Article

    A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma

    The potential benefit of rituximab as adjuvant to high-dose therapy (HDT) has been investigated in patients under 60 years with poor-risk (age-adjusted international prognostic index at 2–3) CD20+ diffuse larg...

    D Coso, C Sebban, O Boulat, P Biron, J Rey, T Aurran… in Bone Marrow Transplantation (2006)

  6. No Access

    Article

    Prise en charge à domicile des neutropénies fébriles courtes après chimiothérapie: résultats et leçons d’une étude pilote menée sur deux ans dans un centre de lutte contre le cancer

    L’étude a pour but de tester la faisabilité d’une prise en charge précoce à domicile des aplasies fébriles sans facteurs de mauvais pronostic. Sur 517 épisodes de neutropénies fébriles enregistrés entre 07/99 ...

    C. Sebban, C. Fuhrmann, D. Pérol, Y. Devaux, H. Ghesquière, S. Galand-Desmé… in Oncologie (2006)

  7. No Access

    Article

    High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL)

    The most appropriate treatment for lymphoblastic lymphomas (LL) remains uncertain. We treated 27 patients with newly diagnosed LL according to an LMT-89 protocol, which is a modified version of the LMT-81 prot...

    E Jabbour, S Koscielny, C Sebban, N Peslin, C Patte, T Gargi, P Biron, C Fermé… in Leukemia (2006)

  8. No Access

    Article

    Tumeurs rares malignes de l’ovaire

    Les tumeurs rares de la sphère ovarienne adulte représentent moins de 10 % des tumeurs ovariennes de l’adulte. Le traitement des tumeurs rares de l’ovaire est actuellement établi comme suit:

    I. Ray-Coquard, J.-P. Guastalla, I. Treilleux, P. Biron, J.-Y. Blay, H. Curé… in Oncologie (2005)

  9. No Access

    Article

    Research controversies in management of oral mucositis

     The management of mucositis is the subject of many controversies, and the optimal treatment is still not known. Several evaluation scoring systems have been described, but no one of these is appropriate to al...

    P. Biron, C. Sebban, R. Gourmet, G. Chvetzoff, I. Philip… in Supportive Care in Cancer (2000)

  10. No Access

    Article

    High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphomas: a single center experience on 18 patients

    Between 1985 and 1996, 18 patients with diffuse centrocytic lymphoma (DCL), including nine patients with an established histological and phenotypic diagnosis of mantle cell lymphoma (MCL), received 19 courses ...

    J-Y Blay, C Sebban, C Surbiguet, M Ouachée, I Philip… in Bone Marrow Transplantation (1998)

  11. No Access

    Chapter and Conference Paper

    No advantage for the use of an early high-dose chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumors

    The results of the treatment of non-seminomatous germ cell tumors (NSGCT) have been dramatically improved by Cisplatin-based chemotherapy regimens and selective indication of surgery. Approximately 80 % of all...

    H. Curé, J. P. Droz, J. L. Pico, P. Biron, P. Kerbrat… in Cancer Treatment An Update (1994)

  12. No Access

    Article

    Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas

    The pharmacokinetics of high-dose fotemustine followed by autologous bone-marrow transplantation during a phase I–II clinical trial in 24 patients with glioblastoma or astrocytoma (grade III–IV) was investigat...

    B. Tranchand, C. Lucas, P. Biron, B. Giroux… in Cancer Chemotherapy and Pharmacology (1993)

  13. No Access

    Article

    Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity

    A 5-day continuous infusion of vincristine (VCR; total dose 4 mg/m2) has been given as part of a high-dose chemoradiotherapy regimen with bone marrow transplantation. Evidence of neurotoxicity, such as weakness, ...

    C. R. Pinkerton, B. McDermott, T. Philip, P. Biron… in Cancer Chemotherapy and Pharmacology (1988)

  14. No Access

    Chapter

    Adrenocortical function in essential hypertension

    For the last 12 years, our main research work has been devoted to the study of the possible relationship of adrenocortical hormones and arterial hypertension in humans. Much clinical and experimental evidence,...

    J. Genest, W. Nowaczynski, E. Koiw, T. Sandor, P. Biron in Essential Hypertension (1960)